« Back
Home /
Pyridoclax

Pyridoclax

Item no.	HY-12527-25mg
Manufacturer	MedChem Express
CASRN	1651890-44-6
Amount	25 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 25 mg 50 mg 5 mg
Category	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Heart & Blood Cancer Uterine, Ovarian & Cervical Cancer
Type	Inhibitors
Specific against	other
Purity	99.95
Citations	[1]Gloaguen C, et al. First evidence that oligopyridines, α-helix foldamers, inhibit Mcl-1 and sensitize ovarian carcinoma cells to Bcl-xL-targeting strategies. J Med Chem. 2015 Feb 26;58(4):1644-68.\|[2]Groo AC, et al. Comparison of 2 strategies to enhance Pyridoclax solubility: Nanoemulsion delivery system versus salt synthesis. Eur J Pharm Sci. 2017 Jan 15;97:218-226.
Smiles	CC1=CC(C2=NC=C(C3=CC=CN=C3)C=C2/C=C/C4=CC=CC=C4)=CN=C1C5=CC=CN=C5
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	MR-29072
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	Bcl-2 Family
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	426.51
Product Description	Pyridoclax is a potential Mcl-1 inhibitor.
Manufacturer - Research Area	Cancer
Solubility	DMSO: 20 mg/mL (ultrasonic)
Manufacturer - Pathway	Apoptosis
Isoform	Mcl-1
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-12527-25mg-safety-datasheet.pdf